Opinion|Videos|September 13, 2024
KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice
Medical experts review long-term data from the KEYNOTE-B61 trial on pembrolizumab and lenvatinib, compare its efficacy and safety across non–clear cell RCC subtypes, and discuss dose management and safety relative to the CLEAR trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the long-term follow-up data from the phase II 2 KEYNOTE-B61trial investigating pembrolizumab and lenvatinib and its the data’s impact in the first-line setting for advanced nccRCC.
- How does the population size of this trial compare to with others?
Please comment on the recent label change based on this these data.
- Building on the long-term follow-up data from the KEYNOTE-B61 trial, how did the response rates and safety data compare across different nccRCC histologies?
- In your practice, how do you approach dose reductions and treatment duration management?
How does the safety data seen in KEYNOTE B61 compare to with what is was seen in the CLEAR trial?
Advertisement
Related to this article
Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5